Mardin BR, Agircan FG, Lange C, Schiebel E (2011) Plk1 controls the Nek2A-PP1γ antagonism in centrosome disjunction. Curr Biol 21, 1145-51 21723128

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S2417-p - CEP250 (human) ▲

Modsite: ETRRLDEsLtQsLTs SwissProt Entrez-Gene Orthologous residues CEP250 (human): S2417‑p, CEP250 iso2 (human): S2361‑p, CEP250 (mouse): S2389‑p, CEP250 (rat): S2365‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  hTERT-RPE1 (epithelial) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE NEK2 (human) PHOSPHATASE PPP1CC (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes BI2536 decrease MG132, RO-3306 decrease VX-680 decrease BI2536 NEK2 (human) inhibit treatment-induced decrease phosphomimicking mutant Downstream Regulation Effect of modification (process):  cell cycle regulation

S2421-p - CEP250 (human) ▲

Modsite: LDEsLtQsLTsPGPV SwissProt Entrez-Gene Orthologous residues CEP250 (human): S2421‑p, CEP250 iso2 (human): S2365‑p, CEP250 (mouse): S2393‑p, CEP250 (rat): S2369‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  hTERT-RPE1 (epithelial) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme PHOSPHATASE PPP1CC (human) KINASE NEK2 (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes BI2536 decrease MG132, RO-3306 decrease VX-680 decrease BI2536 NEK2 (human) inhibit treatment-induced decrease phosphomimicking mutant Downstream Regulation Effect of modification (process):  cell cycle regulation

S15-p - MST2 (human) ▲

Modsite: KSKLKkLsEDsLTkQ SwissProt Entrez-Gene Orthologous residues MST2 (human): S15‑p, MST2 iso2 (human): S43‑p, MST2 (mouse): S15‑p, MST2 (rat): S15‑p Characterization Methods used to characterize site in vivo:  [32P] ATP in vitro, mass spectrometry (in vitro), mutation of modification site Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE PLK1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE PLK1 (human) co-immunoprecipitation, transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme Downstream Regulation Effect of modification (function):  molecular association, regulation Effect of modification (process):  cell cycle regulation Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays NEK2 (human) Disrupts co-immunoprecipitation

S18-p - MST2 (human) ▲

Modsite: LKkLsEDsLTkQPEE SwissProt Entrez-Gene Orthologous residues MST2 (human): S18‑p, MST2 iso2 (human): S46‑p, MST2 (mouse): S18‑p, MST2 (rat): S18‑p Characterization Methods used to characterize site in vivo:  [32P] ATP in vitro, mass spectrometry (in vitro), mutation of modification site Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE PLK1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE PLK1 (human) co-immunoprecipitation, transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme Downstream Regulation Effect of modification (function):  molecular association, regulation Effect of modification (process):  cell cycle regulation Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays NEK2 (human) Disrupts co-immunoprecipitation

S316-p - MST2 (human) ▲

Modsite: LEEEEENsDEDELDs SwissProt Entrez-Gene Orthologous residues MST2 (human): S316‑p, MST2 iso2 (human): S344‑p, MST2 (mouse): S316‑p, MST2 (rat): S316‑p Characterization Methods used to characterize site in vivo:  [32P] ATP in vitro, mass spectrometry (in vitro), mutation of modification site Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE PLK1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE PLK1 (human) co-immunoprecipitation, transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme Downstream Regulation Effect of modification (function):  molecular association, regulation Effect of modification (process):  cell cycle regulation Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays NEK2 (human) Disrupts co-immunoprecipitation